Von Willebrand Disease (vWD) Treatment Market Analysis-2026

Von Willebrand Disease (vWD) Treatment Market Report Analyses competitive environment such as key players, future trends, growths, challenges and acquisitions in the market.
 
 
Spread the Word
Listed Under

Tag:
* Healthcare

Industry:
* Health

Location:
* Seattle - Washington - US

SEATTLE - Sept. 25, 2020 - PRLog -- Von Willebrand Disease (vWD) is a common bleeding disorder caused due to missing or defect in von Willebrand factor (VWF), a clotting factor which helps blood to clot. Low amount of Willebrand factor (VWF) leads to severe and bleeding. There are four types of vWD namely Type 1 vWD, Type 2 vWD, Type 3 vWD, and Acquired vWD. Desmopressin is a common drug used for treatment of vWD, which is an antidiuretic hormone that triggers the release of VWF into the plasma and may increase levels of factor VIII.

Rapid approvals of vWD treatment therapies and drugs from FDA and marketing approvals in different region are expected to fuel growth of von Willebrand Disease (vWD) treatment market in near future. In 2015, the U.S. Food and Drug Administration (FDA) was granted approval for Octapharma's WILATE a replacement therapy for patients suffering from von Willebrand Disease (vWD).

In 2017, European Medicines Agency (EMA) granted authorization for the marketing of VEYVONDI to prevent and treat von Willebrand Disease. VEYVONDI is a replacement therapy developed by Shire plc, which was FDA approved in 2015. Rapid marketing permission of drugs is expected to fuel Von Willebrand Disease (vWD) Treatment Market in near future. The major factor restraining the growth of von Willebrand Disease (vWD) treatment market is lack of awareness about disease and its diagnosis as it is a very rare disease.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/von-willebrand-disease-treatment-market-1154

North America is expected to dominate market due to increasing researches activities for treatment and diagnosis for von Willebrand Disease

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1154

Regional market for the von Willebrand Disease (vWD) treatment market by Coherent Market Insights is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America expected to hold the dominant position in vWD treatment market due to increase in research activities related to treatment and diagnosis of vWD.

Key players are organizing various symposiums to raise awareness about von Willebrand Disease and to increase brand visibility.

In 2017, Octapharma organized a symposium at the International Society on Thrombosis and Haemostasis (ISTH) congress in Berlin to support progress in lifelong treatment for patients with von Willebrand Disease (vWD) and to spread knowledge about their latest replacement therapy WILATE for treatment of von Willebrand Disease.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1154

Contact
Mr. Shah
***@coherentmarketinsights.com
+1-206-701-6702
End
Email:***@coherentmarketinsights.com
Posted By:***@coherentmarketinsights.com Email Verified
Tags:Healthcare
Industry:Health
Location:Seattle - Washington - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share